Opinion | A Welcome FDA Reversal on a Melanoma Drug May 29, 2026 · The Editorial Board · wsj.com read more » The agency will now treat Replimune’s RP1 as ‘an urgent matter.’ Read more »
.png?branch=production&format=jpg&width=1024)
.jpg?branch=production&format=jpg&width=1024)
.jpg?branch=production&format=jpg&width=1024)
.JPG?branch=production&format=jpg&width=1024)
.jpg?branch=production&format=jpg&width=1024)
.png?branch=production&format=jpg&width=1024)
